Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
jRCT2031260265Recruiting
Open-label, single-arm trial of asciminib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Major molecular response at Week 48. Started Jul 2026; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on jRCT2031260265.